⌘K
t
GENinCode Plc announced a trading update for the six months ending 30 June 2025, reporting revenues of £1.6m, a 15% increase from £1.4m in the prior year. The company maintained a gross profit margin of 53% and reported losses of £2.4m for the period. Cash at 30 June 2025 was £2.4m, down from £2.9m at 30 June 2024.
| Date | 26 Aug 2025 |
| Time | 07:00:11 |
| Category | Trading updates |
| ID | 5179W |
26 August 2025
GENinCode Plc
("GENinCode" or the "Company")
Trading update - H1 2025
Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease ("CVD") and risk of ovarian cancer announces a trading update for the 6 months ending 30 June 2025. The first half of 2025 saw continued strengthening of business, with revenues up 15% to £1.6m (30 June 2024 £1.4m) driven by growth across the UK, EU and US business. Gross profit margin remained firm at 53%, (30 June 2024 53%) with losses of £2.4m (30 June 2024 (£2.4m)). Cash at the end of June 2025 was £2.4m (30 June 2024 £2.9m). Trading remains broadly in line with the Board's overall expectations for the full year, with a busy second half period ahead.
FDA De Novo discussions continue to progress with work ongoing to close out the short list of remaining deficiencies. Collaboration discussions on potential US and EU test distribution are also advancing with a major distributer. New clinical data on CARDIO inCode-Score (polygenic risk score) was presented by Kaiser Permanente at the American Society of Preventive Cardiology (ASPC) in Boston in early August with a further presentation at this week's European Society of Cardiology (ESC) Annual Congress in Madrid (Aug 29th - Sept 1st) on the clinical importance of CARDIO inCode-Score in the modulation of cholesterol risk for coronary heart disease.
The Company will present its 2025 Interim Report at the end of September with the reporting date to be confirmed in due course.
For more information visit www.genincode.com
Enquiries:
|
GENinCode Plc |
www.genincode.com or via Walbrook PR |
||
|
Matthew Walls, CEO Paul Foulger, CFO |
|
||
|
|
|
||
|
Cavendish Capital Markets Limited |
Tel: 020 7397 8900 |
||
|
Giles Balleny (Corporate Finance) |
|
||
|
Nigel Birks (Life Sciences Specialist Sales) Harriet Ward (Corporate Broking) |
|
||
|
Dale Bellis / Michael Johnson (Sales) |
|
||
|
|
|
||
|
Walbrook PR Limited |
Tel: 020 7933 8780 or genincode@walbrookpr.com |
||
|
Anna Dunphy / Rachel Broad / Marcus Ulker |
|
||
About GENinCode:
GENinCode Plc is a UK based company specialising in prevention of cardiovascular disease and surveillance testing for ovarian cancer. Cardiovascular disease is the leading cause of death and disability worldwide. GENinCode operates business units in the UK, Europe through GENinCode S.L.U., and in the United States through GENinCode U.S. Inc.
GENinCode predictive technology provides patients and physicians with globally leading diagnostics and risk assessment for precision medicine treatment and preventive care. GENinCode invitro-diagnostic molecular tests combine clinical algorithms and AI bioinformatics to advance patient risk assessment to prevent the onset of cardiovascular disease and ovarian cancer.